Sigma-Aldrich will add BioReliance to its portfolio of products and services aimed at supporting the development of biological drugs. The deal adds BioReliance's $110 M in revenues in the biopharm space and projected double digit growth for 2012 to Sigma's coffers for a cash price of $350 M.
The SAFC group within Sigma-Aldrich focuses on the supply of raw materials to make pharmaceuticals and biopharmaceuticals, does some process development, and offers contract manufacturing and testing services. BioReliance's capabilities in biologics testing, specializes toxicology and in animal health testing will add to SAFC's portfolio. In particular, SAFC will now be able to support testing of both raw materials and final product.
In the production of biological drugs, the combined companies can work together as well in areas like cell line development, banking and testing to support biologics processes -- as well as provide more extensive testing and characterization of final product produced in SAFC plants. Plus with the burgeoning biosimilars area, the combined group will be able to collaborate in areas like glycoanalysis to support product comparability or "biosimilarity".
It's an exciting combination that may promote more of a "one-stop-shop" menu of services to existing clients. Said Sigma-Aldrich President and CEO, Rakesh Sachdev, "As the market continues its focus on biological drug development, our leadership in this area should enable us to build even better, more customer-specific solutions."
Posted by Bruce Lehr Jan 10th 2012.